BECTON DICKINSON & CO

BDX 10-Q · Q1 2026
API behind this page

BDX Q1 2026 request

Playground key active
Request URL /api/financials?ticker=BDX&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 5,252 5,168 +1.6%
Show Business Segments breakouts
BioPharma Systems · BioPharma Systems 429 418 +2.6%
BioPharma Systems · Non Us 279 314 -11.1%
BioPharma Systems · Operating Segments 429 418 +2.6%
BioPharma Systems · US 150 104 +44.2%
Connected Care · Advanced Patient Monitoring 297 271 +9.6%
Connected Care · Medication Management Solutions 835 801 +4.2%
Connected Care · Non Us 119 113 +5.3%
Connected Care · Non Us 156 142 +9.9%
Connected Care · Non Us 275 255 +7.8%
Connected Care · Operating Segments 1,131 1,073 +5.4%
Connected Care · US 178 159 +11.9%
Connected Care · US 678 659 +2.9%
Connected Care · US 857 818 +4.8%
Interventional · Non Us 220 220 0.0%
Interventional · Non Us 108 92 +17.4%
Interventional · Non Us 88 83 +6.0%
Interventional · Non Us 416 396 +5.1%
Interventional · Operating Segments 1,330 1,257 +5.8%
Interventional · Peripheral Intervention 485 473 +2.5%
Interventional · Surgery 418 395 +5.8%
Interventional · Urology and Critical Care 427 389 +9.8%
Interventional · US 265 253 +4.7%
Interventional · US 310 303 +2.3%
Interventional · US 339 306 +10.8%
Interventional · US 914 861 +6.2%
Life Sciences · Biosciences 327 361 -9.4%
Life Sciences · Diagnostic Solutions 439 474 -7.4%
Life Sciences · Non Us 202 208 -2.9%
Life Sciences · Non Us 264 262 +0.8%
Life Sciences · Non Us 466 470 -0.9%
Life Sciences · Operating Segments 766 836 -8.4%
Life Sciences · US 124 153 -19.0%
Life Sciences · US 176 212 -17.0%
Life Sciences · US 300 365 -17.8%
Medical Essentials · Medication Delivery Solutions 1,128 1,124 +0.4%
Medical Essentials · Non Us 435 430 +1.2%
Medical Essentials · Non Us 222 223 -0.4%
Medical Essentials · Non Us 658 654 +0.6%
Medical Essentials · Operating Segments 1,595 1,586 +0.6%
Medical Essentials · Specimen Management 468 462 +1.3%
Medical Essentials · US 693 694 -0.1%
Medical Essentials · US 245 238 +2.9%
Medical Essentials · US 938 932 +0.6%
Show Geography breakouts
Non Us 2,093 2,089 +0.2%
US 3,159 3,080 +2.6%
Show Consolidation Items breakouts
Operating Segments 5,252 5,168 +1.6%
Cost of Revenue 2,841 2,933 -3.1%
Show Business Segments breakouts
BioPharma Systems · Operating Segments 243 232 +4.7%
Connected Care · Operating Segments 501 483 +3.7%
Interventional · Operating Segments 445 404 +10.1%
Life Sciences · Operating Segments 393 385 +2.1%
Medical Essentials · Operating Segments 800 770 +3.9%
Show Consolidation Items breakouts
Operating Segments 2,382 2,273 +4.8%
Selling, General & Administrative 1,393 1,318 +5.7%
Show Business Segments breakouts
BioPharma Systems · Operating Segments 29 29 0.0%
Connected Care · Operating Segments 191 168 +13.7%
Interventional · Operating Segments 262 237 +10.5%
Life Sciences · Operating Segments 147 142 +3.5%
Medical Essentials · Operating Segments 180 165 +9.1%
Show Consolidation Items breakouts
Operating Segments 808 740 +9.2%
Research & Development 306 343 -10.8%
Show Business Segments breakouts
BioPharma Systems · Operating Segments 18 17 +5.9%
Connected Care · Operating Segments 85 80 +6.2%
Interventional · Operating Segments 63 56 +12.5%
Life Sciences · Operating Segments 66 68 -2.9%
Medical Essentials · Operating Segments 47 44 +6.8%
Show Consolidation Items breakouts
Operating Segments 279 265 +5.3%
Integration Restructuring And Transaction Expense 111 92 +20.7%
Show Consolidation Items breakouts
Material Reconciling Items 111 92 +20.7%
Other Operating Income Expense Net 50 28 +78.6%
Show Business Segments breakouts
Connected Care · Operating Segments 3 6 -50.0%
Show Consolidation Items breakouts
Operating Segments 3 6 -50.0%
Total Costs & Expenses 4,700 4,715 -0.3%
Operating Income 552 453 +21.9%
Show Business Segments breakouts
BioPharma Systems · Operating Segments 140 141 -0.7%
Connected Care · Operating Segments 352 336 +4.8%
Interventional · Operating Segments 561 561 0.0%
Life Sciences · Operating Segments 159 240 -33.8%
Medical Essentials · Operating Segments 569 607 -6.3%
Show Consolidation Items breakouts
Operating Segments 1,780 1,884 -5.5%
Interest Expense -153 -155 +1.3%
Interest Income 4 23 -82.6%
Other Non-Operating Income (Expense) -10 -16 +37.5%
Income Before Taxes 393 306 +28.4%
Income Tax Expense (Benefit) 11 3 +266.7%
Net Income 382 303 +26.1%
Show Equity Components breakouts
Retained Earnings 382 303 +26.1%
EPS (Basic) 1.34 1.05 +27.6%
EPS (Diluted) 1.34 1.04 +28.8%
Common Stock Dividends Per Share Declared 1.05 1.04 +1.0%
Operating Expenses (Q) — — —
Show Consolidation Items breakouts
Corporate Non Segment -690 -682 -1.2%
Comprehensive Income 419 359 +16.7%
Wtd Avg Shares (Basic) 285,582 289,505 -1.4%
Wtd Avg Shares (Diluted) 285,845 290,389 -1.6%
Interest Income Expense Net (Q) — — —
Show Consolidation Items breakouts
Material Reconciling Items -149 -132 -12.9%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 740 711 +4.1%
Restricted Cash And Investments Current 284 102 +178.4%
Other Short Term Investments 11 17 -35.3%
Accounts Receivable 2,508 2,638 -4.9%
Inventory Raw Materials Net Of Reserves 940 904 +4.0%
Inventory Work In Process Net Of Reserves 495 453 +9.3%
Inventory Finished Goods Net Of Reserves 2,650 2,502 +5.9%
Inventory 4,085 3,860 +5.8%
Other Assets Current 1,560 1,331 +17.2%
Total Current Assets 9,189 8,659 +6.1%
Non-Current Assets
Property, Plant & Equipment 6,972 6,602 +5.6%
Goodwill 26,620 — —
Show Business Segments breakouts
BioPharma Systems 96 — —
Connected Care 6,093 — —
Interventional 12,767 — —
Life Sciences 648 — —
Medical Essentials 7,015 — —
Other Non-Current Assets 3,035 2,586 +17.4%
Total Assets 54,841 54,665 +0.3%
Intangible Assets 9,009 10,472 -14.0%
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 2,128 2,533 -16.0%
Developed Technology Rights 6,376 7,439 -14.3%
Intellectual Property 505 500 +1.0%
Other Assets
Property Plant And Equipment Gross 15,237 14,156 +7.6%
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment 8,265 7,554 +9.4%
Core And Developed Technology Net 6,376 7,439 -14.3%
Finite Lived Customer Relationships Net 2,128 2,533 -16.0%
Other Intangible Assets Net 521 517 +0.8%
Current Liabilities
Debt Current 2,623 1,318 +99.0%
Accounts Payable And Accrued Liabilities Current 6,138 6,347 -3.3%
Total Current Liabilities 8,761 7,664 +14.3%
Non-Current Liabilities
Long-Term Debt 16,916 17,440 -3.0%
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent 1,067 939 +13.6%
Other Non-Current Liabilities 2,815 3,418 -17.6%
Stockholders' Equity
Common Stock 371 371 0.0%
Additional Paid In Capital Common Stock 20,103 19,768 +1.7%
Retained Earnings 16,704 16,141 +3.5%
Common Stock Shares Held In Employee Trust1 25 25 0.0%
Treasury Stock Value -10,064 -9,425 -6.8%
Accumulated Other Comprehensive Income -1,857 — —
Total Stockholders' Equity 25,282 — —
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment -625 -549 -13.8%
Accumulated Gain Loss Net Cash Flow Hedge Parent 104 72 +44.4%
Accumulated Other Comprehensive Income -1,857 -1,676 -10.8%
Accumulated Translation Adjustment -1,336 -1,199 -11.4%
Additional Paid In Capital 20,103 19,768 +1.7%
Common Stock 371 371 0.0%
Deferred Compensation Share Based Payments 25 25 0.0%
Retained Earnings 16,704 16,141 +3.5%
Treasury Stock Common -10,064 -9,425 -6.8%
Total Liabilities & Equity 54,841 54,665 +0.3%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation & Amortization 614 607 +1.2%
Show Business Segments breakouts
BioPharma Systems · Operating Segments 34 31 +9.7%
Connected Care · Operating Segments 194 194 0.0%
Interventional · Operating Segments 197 200 -1.5%
Life Sciences · Operating Segments 45 44 +2.3%
Medical Essentials · Operating Segments 141 135 +4.4%
Show Consolidation Items breakouts
Corporate Non Segment 3 3 0.0%
Stock-Based Compensation 91 90 +1.1%
Deferred Income Taxes And Tax Credits 29 -151 +119.2%
Increase Decrease In Operating Capital -415 -370 -12.2%
Increase Decreasein Pension Benefit Obligation -2 -2 0.0%
Other Operating Activities Cash Flow Statement -43 216 -119.9%
Net Cash from Operations 657 693 -5.2%
Investing Activities
Capital Expenditures -108 -105 -2.9%
Other Investing Activities -75 -94 +20.2%
Net Cash from Investing -183 204 -189.7%
Financing Activities
Proceeds From Repayments Of Short Term Debt 317 75 +322.7%
Share Repurchases -250 -750 +66.7%
Payments Of Dividends -299 -302 +1.0%
Proceeds From Payments For Other Financing Activities -69 -76 +9.2%
Net Cash from Financing -302 -1,928 +84.3%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 2 -12 +116.7%
Net Change in Cash 174 -1,043 +116.7%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1,025 813 +26.1%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key